CHESS ROBERT 4

What Happened
Robert Chess, a director of Twist Bioscience (TWST), received an equity award of 5,095 shares on February 5, 2026. The shares were granted at a $0 per-share acquisition price (reported as an award/grant, code A). This is a compensation award rather than a purchase or sale.

Key Details

• Transaction date: 2026-02-05; Grant type: Annual Equity Award (code A); reported acquisition price: $0.00.
• Shares reported: 5,095 shares granted.
• Shares owned after transaction: Not specified in the filing.
• Vesting: 100% of these shares vest upon the earlier of (i) the one-year anniversary of the grant or (ii) the first annual meeting of stockholders following the grant, provided the director remains a service provider (footnote F1).
• Beneficial ownership note: The reporting person and his spouse are sole trustees and beneficiaries of the Chess 1997 Trust (footnote F2), indicating the award may be held via that trust.
• Filing timeliness: Report filed Feb 9, 2026; this filing falls within the standard Form 4 reporting window (not flagged as late).

Context
This was a standard annual equity grant to a director (non-cash compensation). Such awards are common for board members and are subject to vesting conditions; they do not represent an immediate open-market purchase or sale.